Jury Finds Some Prevagen Memory Supplement Claims Deceiving

NEW YORK — A New York federal jury has found that some of Quincy Biosciences’ statements regarding the efficacy of its memory supplement Prevagen “had a tendency to deceive,” in an action filed by the Federal Trade Commission and the state’s attorney general.

In a March 11 verdict, the jury in the U.S. District Court for the Southern District of New York found Quincy’s advertising statements regarding the drug’s ability to improve memory within 90 days and reduce memory problems associated with aging were not supported by “competent and reliable scientific evidence.”

But the jury further found that only the …